Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide

Salihoglu A., Ar M. C., Soysal T.

EXPERT REVIEW OF HEMATOLOGY, vol.8, no.6, pp.765-783, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 8 Issue: 6
  • Publication Date: 2015
  • Doi Number: 10.1586/17474086.2015.1091301
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.765-783
  • Istanbul University Affiliated: Yes


B-cell lymphoproliferative disorders comprise 85% of Non-Hodgkin's lymphomas. Despite successful chemoimmunotherapy regimens, responses are not durable and the outcome is fatal in a considerable portion of patients. There is an inevitable need for less toxic and more potent therapeutic agents. Over the recent years, a plethora of agents including monoclonal antibodies, Bcl-2 antagonists, tyrosine kinase inhibitors, cyclin-dependent kinase inhibitors, mTOR inhibitors and immunomudulatory drugs have been developed in B-cell malignancies. The aim of this paper is to focus on B-cell receptor signaling inhibitors and lenalidomide as an immunomodulatory drug and to provide insight on how and when to incorporate these agents into the treatment algorithms.